Kate Brain
Professor of Health Psychology
Cardiff University
Chairing: Inequalities in cancer detection and diagnosis
Carmen Guerra
Ruth C. and Raymond G. Perelman Professor of Medicine
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Chairing: Inequalities in cancer detection and diagnosis
Sam Janes
Director of Medicine
University College London (UCL)
Chairing: Understanding pre-cancers to enable early detection
Irene Ghobrial
Professor of Medicine
Dana-Farber Cancer Institute
Chairing: Understanding pre-cancers to enable early detection
Yoryos Lyratzopoulos
Professor of Cancer Epidemiology
University College London (UCL)
Chairing: Risk stratification to inform early detection
Sapna Syngal
Director of Research, Division of Cancer Genetics and Prevention, Director of Strategic Planning for Prevention and Early Cancer Detection, Dana-Farber Cancer Institute
Leader, Cancer Risk, Prevention, and Early Detection Program, Dana-Farber/Harvard Cancer Center, Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Chairing: Risk stratification to inform early detection
Matthew Thompson
Professor, University of Washington Department of Family Medicine & Clinical Research Scientist
Google Inc, and University of Washington
Chairing: Multicancer early detection – beyond ctDNA
Claude Chelala
Professor of Bioinformatics
Barts Cancer Institute, Queen Mary University of London
Chairing: Multicancer early detection – beyond ctDNA
Jon Emery
Herman Professor of Primary Care Cancer Research
University of Melbourne
Chairing: Panel – What lessons did we learn from COVID-19 that can be applied to early cancer detection?
Larry Kessler
Professor, Health Systems and Population Health
University of Washington/MCED Consortium
Chairing: Panel – The health economics of early detection
David Crosby
Head of Prevention and Early Detection Research
Cancer Research UK
Chairing: ‘We need to shift early detection of cancer away from medical practices and hospitals and into the community’ Great Debate & ‘All cancer screening must be reserved for ‘high risk’ population’ Great Debate
